drugset / Trial / NCT00623753

Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults

NCT00623753 ↗

Phase 1 Terminated 3 enrolled St. Jude Children's Research Hospital
NaSingle-groupOpen-labelPrevention

Summary

Vaccines have been very successful in preventing viral infections such as hepatitis B and the measles. Viral vaccines work by causing a person's immune system to make cells that will work against the virus. Due to the success in treating other viral infections, scientists are trying to develop a vaccine for human immunodeficiency virus (HIV). HIV infection is the cause of acquired immune deficiency syndrome (AIDS). AIDS is one of the most serious viral infections we know. This is a research study to evaluate the safety of a possible vaccine against HIV. Researchers want to determine that a person's immune system can respond to the HIV before he or she is exposed to it. Therefore that person may be able to be protected from infection with HIV.

Timeline

Start
2007-05
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject EnvDNA Vaccine 100 ug Intramuscular
Subject EnvPro Vaccine 100 ug Intramuscular
Subject PolyEnv1 Vaccine 107 unknown Subcutaneous